From the Journals

Incidence, prognosis of second lung cancers support long-term surveillance


 

FROM LUNG CANCER

Study details

For the study, Dr. Varlotto and coinvestigators used data from SEER-13 and SEER-18 to identify patients with a lung cancer diagnosis during 1998-2013, and data from SEER-9, covering the years 1985-2014, to calculate rates of second cancers occurring 4-10 years after a first lung cancer.

Analyses were based on 58,758 patients with a surgically resected first primary lung cancer (55.9% with early-stage disease) and 384 patients with a surgically resected second primary lung cancer (77.6% with early-stage disease). Median follow-up was 76 months for the former and 46 months for the latter.

Results showed that in the 4-10 years after a first lung cancer diagnosis, the age-adjusted incidence of second lung cancers rose by study year but remained less than that of all other second cancers combined until the mid-2000s. Among women, incidence started rising sharply in 2001 and significantly exceeded that of all other second cancers starting in 2005.

In the entire population of study patients, propensity-adjusted analyses showed that second lung cancers were similar to first lung cancers on overall survival (P = .1726) but had worse lung cancer–specific survival (P = .0143). However, in the subset of patients with early-stage resectable disease, second and first lung cancers were similar on both overall survival (P = .3872) and lung cancer–specific survival (P = .1276).

Dr. Varlotto disclosed that he had no conflicts of interest. The study was funded by the Department of Radiation Oncology, University of Massachusetts. Dr. Antonoff disclosed that she had no relevant conflicts of interest.

SOURCE: Varlotto JM et al. Lung Cancer. 2020;147:115-122.

Pages

Recommended Reading

ctDNA clearance tracks with PFS in NSCLC subtype
AVAHO
Heavy toll from ongoing cancer referral delays
AVAHO
CCC19, other registries help define COVID/cancer landscape
AVAHO
Higher death rate seen in cancer patients with nosocomial COVID-19
AVAHO
OK to treat many cancer patients despite pandemic, says ESMO
AVAHO
Study: Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19
AVAHO
Artificial intelligence matches cancer genotypes to patient phenotypes
AVAHO
Chemo-free management of mesothelioma on horizon
AVAHO
Sintilimab scintillates in first-line nonsquamous NSCLC
AVAHO
NSCLC success story: Mortality down, survival improved
AVAHO